Search results for "Neurologi"

showing 10 items of 1189 documents

Revised Definition of Neuropathic Pain and Its Grading System: An Open Case Series Illustrating Its Use in Clinical Practice

2009

The definition of neuropathic pain has recently been revised by an expert committee of the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG) as "pain arising as direct consequence of a lesion or disease affecting the somatosensory system," and a grading system of "definite," "probable," and "possible" neuropathic pain has been introduced. This open case series of 5 outpatients (3 men, 2 women; mean age 48 +/- 12 years) demonstrates how the grading system can be applied, in combination with appropriate confirmatory testing, to diagnosis neuropathic conditions in clinical practice. The proposed grading system includes a dynamic algorithm …

AdultMalemedicine.medical_specialtyMEDLINEPainPhysical examinationDiseaseNeurological disorderSeverity of Illness IndexDiagnosis DifferentialCraniomandibular DisordersBrown-Sequard SyndromeSeverity of illnessmedicineHumansMedical History TakingSomatoform DisordersProspective cohort studyPhysical ExaminationPain Measurementmedicine.diagnostic_testbusiness.industryNeuromyelitis OpticaGeneral MedicineMiddle AgedTrigeminal Neuralgiamedicine.diseaseSurgeryNeuropathic painNeuralgiaPhysical therapyNeuralgiaFemaleUlnar NeuropathiesbusinessThe American Journal of Medicine
researchProduct

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

2014

Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-term clinical progression in a large cohort of multiple sclerosis (MS) patients. Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression of Expanded Disability Status…

AdultMalemedicine.medical_specialtyMagnetic resonance imaging follow-up multiple sclerosis clinical predictors gray matter atrophypredictormultiple sclerosisDisease courseDisability EvaluationMultiple Sclerosis Relapsing-RemittingInternal medicinefollow-upmedicineHumansSecondary progressiveExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionFollow up studiesMagnetic resonance imagingclinical predictorsMiddle Agedmedicine.diseaseMagnetic Resonance Imaginggray matter atrophyCross-Sectional StudiesNeurologymultiple sclerosiDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessNuclear medicineClinical progressionMRIFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Magnetic Resonance Imaging Surveillance for Vestibular Schwannoma After Microsurgical Resection Using a Retrosigmoid Transmeatal Approach.

2020

BACKGROUND Vestibular schwannoma (VS) is a benign, usually slow-growing tumor. The drawback of radical microsurgical VS resection is the increased likelihood of neurologic injury, forcing surgeons to leave a tumor remnant in some cases. We evaluated the prognostic value of magnetic resonance imaging (MRI) enhancement patterns to determine the risk of tumor regrowth. METHODS This clinical study included 30 patients (20 women and 10 men) with VS who underwent surgery via a retrosigmoid transmeatal approach. The extent of resection was assessed by MRI 6 months after surgery. Two subtypes of intracanalicular linear enhancement were defined: linear enhancement of the walls of the internal audito…

AdultMalemedicine.medical_specialtyMicrosurgeryContrast MediaGadoliniumSchwannomaNeurosurgical Procedures03 medical and health sciencesYoung Adult0302 clinical medicinemedicineHumansAgedVestibular systemmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingNeuroma AcousticMiddle Agedmedicine.diseaseCerebellopontine angleImage EnhancementFacial nerveMagnetic Resonance ImagingMicrosurgical treatmentFacial paralysisNeurologic injuryTreatment Outcome030220 oncology & carcinogenesisEar InnerSurgeryFemaleNeurology (clinical)RadiologyNeoplasm Recurrence Localbusiness030217 neurology & neurosurgeryWorld neurosurgery
researchProduct

Prevalence and incidence of multiple sclerosis in the city of Monreale, Italy

1997

The prevalence and incidence of multiple sclerosis (MS) in the city of Monreale, southern Italy were ascertained 10 years after a preliminary study in the same area. The study was undertaken in a population of 26,256 people. The patients were classified according to Poser’s criteria. The prevalence of MS on 31 December 1991 was 72.4 per 100,000 population. The incidence of MS for the period 1981–1991 was 3.3/100,000 per year. The mean period between onset and diagnosis of MS was 4.9 years for those patients found during this survey and 9.2 years for those in the first study. This study shows an increase of MS prevalence in Monreale city and a high incidence. The findings parallel the reduct…

AdultMalemedicine.medical_specialtyMultiple SclerosisAdolescentEpidemiologyPopulationAge DistributionLag timeEpidemiologyPrevalencemedicineHumansMultiple sclerosiSex DistributionChildeducationAgededucation.field_of_studybusiness.industryIncidenceMultiple sclerosisIncidence (epidemiology)Infant NewbornInfantMiddle Agedmedicine.diseaseHealth SurveysItalyNeurologyChild PreschoolSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessDemographyJournal of Neurology
researchProduct

Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients

2009

Abstract Multiple Sclerosis (MS) patients present a decrease of antioxidants and neuroprotective and immunoregulatory vitamins and an increase of total homocysteine (tHcy), cholesterol (CHL), HDL-cholesterol, and of cellular stress markers, variably associated with the different phases of the disease. We compared the blood levels of uric acid, folic acid, vitamins B12, A, and E, tHcy, CHL, HDL-cholesterol, and triglycerides in forty MS patients during a phase of clinical inactivity with those of eighty healthy controls, matched for age and sex. We found higher levels of tHcy (p = 0.032) and of HDL-cholesterol (p = 0.001) and lower levels of vitamin E (p = 0.001) and the ratio vitamin E/CHL …

AdultMalemedicine.medical_specialtyMultiple SclerosisAdolescentHomocysteineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBlood lipidsClinical nutritionBiologyAntioxidantschemistry.chemical_compoundFolic AcidEndocrinologyHigh-density lipoproteinSettore BIO/10 - BiochimicaInternal medicinemedicineHumansShort PaperVitamin B12Homocysteinelcsh:RC620-627TriglyceridesBiochemistry medicalCholesterolVitamin EBiochemistry (medical)VitaminsMiddle AgedLipidsUric Acidlcsh:Nutritional diseases. Deficiency diseasesEndocrinologychemistryCase-Control StudiesUric acidSettore MED/26 - NeurologiaFemalelipids (amino acids peptides and proteins)Lipids in Health and Disease
researchProduct

High Prevalence and Fast Rising Incidence of Multiple Sclerosis in Caltanissetta, Sicily, Southern Italy

2006

<i>Background:</i> Epidemiological studies conducted in Sicily and Sardinia, the two major Mediterranean islands, showed elevated incidence and prevalence of multiple sclerosis (MS)and a recent increase in disease frequency. <i>Objective:</i> To confirm the central highlands of Sicily as areas of increasing MS prevalence and elevated incidence, we performed a follow-up study based on the town of Caltanissetta (Sicily), southern Italy. <i>Methods:</i> We made a formal diagnostic reappraisal of all living patients found in the previous study performed in 1981. All possible information sources were used to search for patients affected by MS diagnosed accordi…

AdultMalemedicine.medical_specialtyMultiple SclerosisAdolescentMultiple sclerosis incidence Prevalence SicilyEpidemiologyAge DistributionEpidemiologyPrevalencemedicineHumansSex DistributionSicilyAgedHigh prevalencebusiness.industryIncidenceMultiple sclerosisIncidence (epidemiology)Urban HealthMiddle Agedmedicine.diseaseHealth SurveyshumanitiesFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessMediterranean IslandsFollow-Up StudiesDemographyNeuroepidemiology
researchProduct

Multiple sclerosis severity score: Using disability and disease duration to rate disease severity

2005

Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. I…

AdultMalemedicine.medical_specialtyMultiple SclerosisDatabases FactualCross-sectional studyModels NeurologicalDiseaseSUSCEPTIBILITYSeverity of Illness IndexCohort StudiesDisability EvaluationPredictive Value of TestsRecurrenceSeverity of illnessmedicineHumansLongitudinal StudiesAge of OnsetModels StatisticalExpanded Disability Status Scalebusiness.industryMultiple sclerosisOUTCOME MEASUREReproducibility of ResultsNATURAL-HISTORYMiddle AgedPrognosismedicine.diseaseCross-Sectional StudiesPredictive value of testsDisease ProgressionPhysical therapyFemaleFranceNeurology (clinical)Age of onsetbusinessCohort study
researchProduct

Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center

2020

Abstract Background Alemtuzumab, is a compound approved for highly active MS, and, in Europe, employed after the use of other disease-modifying treatments (DMTs) with an escalation approach or used as a first therapeutic option. The occurrence of secondary autoimmune adverse events and or infections can differ depending on the employed approach. Objective To evaluate the efficacy and safety of alemtuzumab in real-world MS population that encompassed patients previously treated with other DMTs. Methods 35 patients, treated with alemtuzumab in a single MS Center, were followed for at least 36 months. The study investigated the prevalence of patients reaching the phase of the non-active diseas…

AdultMalemedicine.medical_specialtyMultiple SclerosisEfficacyPopulationDisease03 medical and health sciences0302 clinical medicineInternal medicinePost-hoc analysisOutcome Assessment Health CaremedicineHumansImmunologic Factors030212 general & internal medicineAdverse effecteducationAlemtuzumabeducation.field_of_studybusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseasePancytopeniaProgression-Free SurvivalNeurologyItalyAdverse eventsDisease ProgressionAlemtuzumabFemaleSettore MED/26 - NeurologiaNeurology (clinical)Autoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis

2018

ObjectiveTo investigate clinical and radiological outcomes of women with relapsing-remitting multiple sclerosis (RRMS) undergoing abortion.MethodsAn independent, multicentre retrospective study was conducted collecting data from eight Italian MS centres. We compared the preconception and postabortion annualised relapse rate (ARR) and number of Gadolinium enhancing (Gd+) lesions, by analyses of covariance. Variables associated with postabortion clinical and MRI activity were investigated using Poisson regression models; each abortion was considered as a statistical unit.ResultsFrom 1995 to 2017, we observed 188 abortions (17 elective) in 153 women with RRMS. Abortions occurred after a mean t…

AdultMalemedicine.medical_specialtyMultiple SclerosisGadoliniumNeuroimagingDiseaseRelapsing-RemittingAbortionSettore MED/26annualised relapse rateYoung Adult03 medical and health sciencessymbols.namesakeMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrencemedicineHumansPoisson regressionRetrospective StudiesInflammationPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetricsMultiple sclerosisInducedAbortionAbortion InducedRetrospective cohort studymedicine.diseaseMagnetic Resonance Imaginggadolinium enhancing lesionDiscontinuationPsychiatry and Mental healthPregnancy Maintenancemultiple sclerosisymbolsSettore MED/26 - NeurologiaFemaleSurgerypregnancyNeurology (clinical)business030217 neurology & neurosurgeryabortion; annualised relapse rate; gadolinium enhancing lesion; multiple sclerosis; pregnancyJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

2009

Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender…

AdultMalemedicine.medical_specialtyMultiple SclerosisPropensity scoreDiseasegender; interferon beta; multiple sclerosis; observational study; propensity scoreLower riskSeverity of Illness IndexMultiple sclerosis Interferon beta Gender Observational study Propensity scoreCohort StudiesDisability EvaluationYoung AdultSex Factorsgender multiple sclerosis treatment interferonDouble-Blind MethodInternal medicineObservational studymedicinegenderConfidence IntervalsOdds RatioProduct Surveillance PostmarketingHumansImmunologic FactorsMultiple sclerosiProportional Hazards ModelsExpanded Disability Status ScaleProportional hazards modelbusiness.industryMultiple sclerosisDrug Administration RoutesInterferon-betamedicine.diseaseInterferon betaSurgeryNeurologyItalyCohortPropensity score matchingRegression AnalysisSettore MED/26 - NeurologiaObservational studyFemaleNeurology (clinical)business
researchProduct